Amorphical has announced positive final long-term follow-up data from its Phase II clinical trial evaluating its investigational nano-amorphous Calcium Carbonate (ACC) therapy, for the treatment of moderate-to-severe Crohn’s disease. 

The full data analysis, including a cohort of patients who completed follow-up extending up to 48 weeks post-baseline, confirms the positive interim results reported in September 2025.  

The data demonstrates meaningful clinical improvement and the durability of the clinical response when nano-amorphous ACC is added to best available standard of care (BAT). 

“The consistency of the final data and the powerful signal of sustained remission over nearly two years is a significant validation for this programme and the potential of our nano-amorphous technology platform,” said Eden Ben, Chief Executive Officer of Amorphical. “Completing the analysis with these confirmed results de-risks our programme and provides a strong foundation for our planned regulatory discussions.” 

The trial was conducted at Soroka University Medical Center under the supervision of the ethical committee in Israel. The company is now focused on advancing this therapy into the next phase of clinical development. 

“The sustained clinical remission observed with nano-amorphous ACC over long-term follow-up is a compelling finding for patients with moderate-to-severe Crohn’s disease,” said Dr Arik Segal, lead investigator from the Department of Gastroenterology at Soroka University Medical Center. “The durability of response strengthens the potential of this novel approach to deliver meaningful, lasting benefit.” 

The data supports the therapy’s novel dual mechanism – it is designed for controlled activity in the small intestine, where it locally neutralises acidity at inflamed sites and provides bioavailable calcium that supports epithelial repair. Five out of eight patients achieved continuous clinical remission through Week 48 and beyond. 

Amorphical is also advancing programmes in pancreatic cancer, hypoparathyroidism, and osteoporotic fractures.

Diana Turner, Deputy Editor, DDW